I’ve only seen this in the ngio 10k: “The Phase II trial began enrolling patients in September of 2019, and is expected to enroll 29 patients. The SARS-CoV-2 epidemic temporarily paused enrollment for the first half of the year, however, patient screening has restarted and enrollment is continuing.”
(1)
(0)
Generex Biotechnology Corp. (GNBTQ) Stock Research Links